[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Narducci F, Orazi G, Cosson M: [Ovarian cyst: surgical indications and access]. J Gynecol Obstet Biol Reprod (Paris); 2001 Nov;30(1 Suppl):S59-67
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian cyst: surgical indications and access].
  • Laparoscopic treatment of adnexal masses is indicated when all criteria of a benign lesion are present: transvaginal ultrasound demonstrates a mass < 5 cm, with liquid or dermoid content, with less than 3 fine partitions (< 3 mm), a thin wall (< 3 mm), no vegetations, normal Doppler.
  • Laparoscopy is also indicated for "benign" cysts measuring 5 to 10 cm if laparoscopy is feasible.
  • Since the benign or malignant nature of an ovarian mass cannot be determined macroscopically, precaution must be taken to avoid potential laparoscopic dissemination: use of an extraction pouch, instrument cleaning, cytotoxic agent (chlorexidine or povidone-iodine) for trocar tracts, prevention of gas leakage, 3-plane suture of trocar orifices measuring > 10 mm, short interval between laparoscopic diagnosis of cancer and onset of chemotherapy or complete surgery (1 week).
  • If several suspicious elements are found, median laparotomy is often recommended, particularly in case of suspected cancer with extra-ovarian involvement, or if there is a risk of peroperative rupture.
  • [MeSH-major] Gynecologic Surgical Procedures. Ovarian Cysts / surgery
  • [MeSH-minor] Biopsy. Female. Humans. Laparoscopy. Ovarian Neoplasms. Risk Factors. Rupture, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11917377.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down


2. Malati T, Kumari GR, Yadagiri B: Application of tumor markers in ovarian malignancies. Indian J Clin Biochem; 2001 Jul;16(2):224-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of tumor markers in ovarian malignancies.
  • Ovarian cancer is the fifth leading cause of death in women.
  • Until recently, detection of early stage ovarian cancer has been difficult since it is usually nonpalpable and asymptomatic.
  • The definitive diagnosis of an ovarian mass is a common problem in gynecologic patients with adnexal mass.
  • The clinical application of serum concentration of CA 125, AFP and hCG is of great help not only as diagnostic aid but also in monitoring efficacy of any treatment modality like chemotherapy, radiotherapy or surgical resection.
  • Additionally, evaluation of tumor marker concentration helps in predicting early biochemical recurrence and in prognostication in different types of ovarian malignancies.
  • The ability to differentiate a malignant mass from a benign pelvic mass pretherapeutically could be enhanced optimally by additional use of tumor markers such as cancer antigen CA-125, alphafetoprotein and human chorionic gonadotrophin in pre-and postmenopausal women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1991 Dec;165(6 Pt 1):1857-64 [1721486.001]
  • [Cites] Obstet Gynecol Clin North Am. 1989 Mar;16(1):237-52 [2664620.001]
  • [Cites] Obstet Gynecol. 1986 Sep;68(3 Suppl):84S-85S [3016631.001]
  • [Cites] Indian J Cancer. 1999 Jun-Dec;36(2-4):163-78 [10921221.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 2):S28-33 [7835806.001]
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):179-87 [10228898.001]
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):200-6 [10228901.001]
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):216-20 [10228904.001]
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):231-7 [10228907.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):196-201 [3471273.001]
  • (PMID = 23105325.001).
  • [ISSN] 0970-1915
  • [Journal-full-title] Indian journal of clinical biochemistry : IJCB
  • [ISO-abbreviation] Indian J Clin Biochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453631
  • [Keywords] NOTNLM ; AFP / CA 125 / Ovarian malignancy / hCG / tumor marker
  •  go-up   go-down


3. Chu SM, Ming YC, Chao HC, Lai JY, Chen JC, Yung CP, Luo CC: Ovarian tumors in the pediatric age group: 37 cases treated over an 8-year period. Chang Gung Med J; 2010 Mar-Apr;33(2):152-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian tumors in the pediatric age group: 37 cases treated over an 8-year period.
  • BACKGROUND: Ovarian tumors have generally been considered rare in the pediatric age group.
  • We reported our experience dealing with pediatric ovarian tumors during an 8-year period.
  • METHODS: Between January 1998 and December 2006, 37 girls with ovarian tumors were treated at the Department of Pediatric Surgery, Chang Gung Childrenfs Medical Center.
  • Modes of clinical presentation, pathology diagnosis, methods of treatment and clinical outcome were retrospectively analyzed.
  • RESULTS: Twenty-nine of the 37 patients were symptomatic with abdominal pain, abdominal distention or the presence of a palpable mass, reduction in appetite or nausea and vomiting and precocious puberty.
  • Thirty patients had benign disease and 7 had malignant tumors.
  • All underwent salpingo-oophorectomy and received chemotherapy following their initial operation and remained free of disease at 8 months to 6 years of follow-up.
  • CONCLUSIONS: In our studies, most ovarian tumors were benign.
  • Epithelial cysts and teratomas were the most common benign lesions, and germ cell tumors were the most common malignancy.
  • With accurate staging, complete resection, and chemotherapy for malignant tumors, patients are expected to have excellent survival rates.
  • [MeSH-major] Ovarian Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438667.001).
  • [ISSN] 2309-835X
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


Advertisement
4. Papoutsis D, Rodolakis A, Haidopoulos D, Sotiropoulou M, Antsaklis A: Peritoneal implantations of papillary serous ovarian cystadenocarcinoma 13 days after initial laparoscopic treatment for a presumed benign ovarian cyst. Eur J Gynaecol Oncol; 2009;30(1):103-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal implantations of papillary serous ovarian cystadenocarcinoma 13 days after initial laparoscopic treatment for a presumed benign ovarian cyst.
  • We report a case of a 24-year-old female who underwent laparoscopy for a presumed benign ovarian mass.
  • Frozen sections at laparoscopy initially revealed a borderline papillary serous ovarian tumour.
  • Final histology showed an invasive papillary serous ovarian tumor (grade 1).
  • Subsequent staging laparotomy conducted 13 days later revealed peritoneal implantations thus upgrading the initially thought Stage Ia papillary serous ovarian tumour at laparoscopy to Stage IIc.
  • The patient after laparotomy had an uneventful postoperative course and received six cycles of chemotherapy based on taxol and carboplatin.
  • A short review of the literature is also presented, concerning the factors which affect the patient's prognosis in cases of unexpected ovarian malignancy found during laparoscopy that are treated with subsequent staging laparotomy.
  • [MeSH-major] Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Frozen Sections. Humans. Laparoscopy. Neoplasm Staging. Paclitaxel / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Papillary cystadenocarcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317271.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Lanitis S, Sivakumar S, Behranwala K, Zacharakis E, Al Mufti R, Hadjiminas DJ: A case of Meigs syndrome mimicking metastatic breast carcinoma. World J Surg Oncol; 2009;7:10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast cancer and ovarian malignancies are known to be associated.
  • Nevertheless, benign ovarian masses can mimic this clinical picture when they are associated with Meigs' syndrome making the work-up and management of these patients challenging.
  • Pre-treatment staging investigations showed a 13.5 cm mass in her left ovary, a small amount of ascites and a large right pleural effusion.
  • Serum tumour markers showed a raised CA125 supporting the malignant nature of the ovarian mass.
  • After a good response to the hormone manipulation, the patient had breast conserving surgery, axillary sampling and laparoscopic excision of the ovarian mass which was eventually found to be a benign ovarian fibroma.
  • CONCLUSION: Despite the high probability of disseminated malignancy when an ovarian mass associated with ascites if found in a patient with a breast cancer and pleural effusion, clinicians should be aware about rare benign syndromes, like Meigs', which may mimic a similar picture and mislead the diagnosis and management plan.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroma / diagnosis. Meigs Syndrome / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. CA-125 Antigen / blood. Diagnosis, Differential. Female. Gynecologic Surgical Procedures. Humans. Mastectomy. Middle Aged. Nitriles / therapeutic use. Pleural Effusion / diagnosis. Pleural Effusion / drug therapy. Triazoles / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. LETROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2000 Jul;216(1):242-7 [10887255.001]
  • [Cites] Breast Cancer. 2006;13(4):344-8 [17146160.001]
  • [Cites] Am J Clin Oncol. 1989 Oct;12(5):369-74 [2801596.001]
  • [Cites] J Comput Assist Tomogr. 1990 Sep-Oct;14(5):833-4 [2398172.001]
  • [Cites] Gynecol Obstet Invest. 1992;33(1):54-8 [1563658.001]
  • [Cites] J Surg Oncol. 1994 Jun;56(2):71-4 [8007681.001]
  • [Cites] Obstet Gynecol. 1994 Sep;84(3):449-52 [8058246.001]
  • [Cites] Radiographics. 1994 Jul;14(4):747-60; discussion 761-2 [7938766.001]
  • [Cites] J Anat. 1995 Jun;186 ( Pt 3):453-67 [7559120.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Jan;82(1):97-9 [10192495.001]
  • [Cites] Am J Obstet Gynecol. 1954 May;67(5):962-85 [13148256.001]
  • [Cites] J Int Coll Surg. 1964 Dec;42:625-30 [14209105.001]
  • [Cites] Obstet Gynecol. 2005 Mar;105(3):507-13 [15738016.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:315-8 [16515612.001]
  • [Cites] J Thorac Imaging. 2003 Apr;18(2):100-3 [12700485.001]
  • (PMID = 19161612.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-125 Antigen; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  • [Other-IDs] NLM/ PMC2633000
  •  go-up   go-down


6. Păun I, Mogoş D, Păun M, Teodorescu M, Florescu M, Tenovici M, Mogoş G: [Diseases mimicking advanced-stage epithelial ovarian cancer]. Chirurgia (Bucur); 2010 Jul-Aug;105(4):541-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diseases mimicking advanced-stage epithelial ovarian cancer].
  • [Transliterated title] Afecţiuni mimând cancerul ovarian epitelial în stadiu avansat.
  • This paper draws attention towards 3 cases with different pathologies all of which suggesting however both clinically and by imaging means as the most likely diagnosis advanced-stage epithelial ovarian cancer since all these three postmenopausal women had been admitted to the hospital with ascites, pelvic masses and deterioration of the physical wellbeing (fatigue, decreased appetite, weight loss, pallor).
  • Findings during exploratory laparotomy on all these three pacients included ascites (hemorragic in one case) diffuse tumorous implants throughout the abdominal and pelvic peritoneal surfaces (in two cases) and the ovarian tumour.
  • Postoperatively, the final histopathologic diagnoses consisted of primary peritoneal carcinoma (one pacient), peritoneal tuberculosis (TB, one pacient) and hepatic cirrosis with an incidental benign adnexial mass (one pacient).
  • Moreover, nonmalignant ovarian tumours were certified in all three cases under current presentation.
  • The differential diagnosis of the ovarian cancer and a tailored approach to treatment for each of these three pathologic entities will also be described in detail.
  • [MeSH-major] Carcinoma / diagnosis. Cystadenoma / diagnosis. Liver Cirrhosis / diagnosis. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Peritonitis, Tuberculous / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Antitubercular Agents / therapeutic use. Ascites / diagnosis. Diagnosis, Differential. Diagnostic Errors. Drug Therapy, Combination. Female. Humans. Middle Aged. Neoplasm Staging. Ovariectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20941979.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antitubercular Agents
  •  go-up   go-down


7. Lin CH, Liu FS, Ho ES: Transitional cell carcinoma of the ovary. Taiwan J Obstet Gynecol; 2006 Sep;45(3):268-71
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Transitional cell carcinoma (TCC) of the ovary is a rare, recently recognized, subtype of ovarian surface epithelial cancer.
  • We present a case of TCC of the ovary, managed by staging operation and followed by postoperative chemotherapy with carboplatin and cyclophosphamide.
  • CASE REPORT: A 67-year-old postmenopausal woman presented with a 2-year history of progressive enlargement of an abdominal mass.
  • Pelvic sonography and abdominal computed tomography showed a pelvic mass measuring 210 x 165 x 203 mm.
  • After surgery, the pathologic report of the left ovarian tumor was TCC, grade 2-3, stage IA.
  • The patient then underwent four cycles of postoperative chemotherapy with carboplatin and cyclophosphamide.
  • CA-125 levels declined to within the normal range after the first cycle of chemotherapy.
  • CONCLUSION: TCC of the ovary is a rare subtype of epithelial ovarian cancer.
  • It differs from malignant Brenner tumor by the absence of a benign or borderline Brenner component.
  • Surgical resection is the primary therapeutic approach, and patient outcomes after chemotherapy are better than for other types of common epithelial ovarian cancers.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Hysterectomy. Ovarian Neoplasms / surgery. Ovariectomy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Fallopian Tubes / surgery. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175479.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Oltmann SC, Fischer A, Barber R, Huang R, Hicks B, Garcia N: Pediatric ovarian malignancy presenting as ovarian torsion: incidence and relevance. J Pediatr Surg; 2010 Jan;45(1):135-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric ovarian malignancy presenting as ovarian torsion: incidence and relevance.
  • PURPOSE: With ovarian torsion, concern for underlying malignancy in the enlarged ovary has previously driven surgeons to resection.
  • Detorsion alone has been recommended to allow for resolution of edema of the ovary with follow-up ultrasound surveillance to evaluate for a persistent mass, yet is not routine practice.
  • However, the incidence of malignancies presenting as ovarian torsion is not documented.
  • METHOD: After institutional review board exemption (IRB#-022008-095), a 15(1/2)-year retrospective review was conducted to identify cases of operative ovarian torsion in our medical center.
  • Tumors with neoplastic pathology (malignant and benign) were analyzed and compared with all reported cases in the literature.
  • RESULTS: A total of 114 patients (mean +/- SEM age, 10 years, 2 days to 19 years +/- 0.53) with operatively proven ovarian torsion were identified.
  • Four malignancies (3.5%) and 26 benign neoplasms (23%) were present in this age group.
  • All were stage I: the former were stage IA and cured with resection alone, and 1 was a stage IB dysgerminoma, which required chemotherapy.
  • The literature yielded a total of 593 cases of operative ovarian torsion with 9 (1.5%) malignancies and 193 (33%) benign neoplasms.
  • CONCLUSION: By combining our series with 13 in the literature, a 1.8% malignancy rate occurred in 707 patients with ovarian torsion, markedly less than the reported malignancy rate of 10% in children with ovarian masses.
  • These data further support the implementation of operative detorsion and close postoperative ovarian surveillance, with reoperation for persistent masses.
  • [MeSH-major] Ovarian Diseases / diagnosis. Ovarian Neoplasms / diagnosis. Torsion Abnormality / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20105593.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


9. Buttin BM, Cohn DE, Herzog TJ: Meigs' syndrome with an elevated CA 125 from benign Brenner tumors. Obstet Gynecol; 2001 Nov;98(5 Pt 2):980-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meigs' syndrome with an elevated CA 125 from benign Brenner tumors.
  • BACKGROUND: Meigs' syndrome refers to solid, benign ovarian tumors, ascites, hydrothorax, and resolution of these signs after surgery.
  • Meigs' syndrome with an elevated CA 125 secondary to benign Brenner tumors is exceedingly rare.
  • CASE: A postmenopausal woman presented with a large pelvic mass, ascites, and a right pleural effusion.
  • Ascitic fluid, pleural fluid, and fine needle aspiration of the mass were without evidence of malignancy.
  • Exploratory laparotomy with total abdominal hysterectomy and bilateral salpingo-oophorectomy revealed benign Brenner tumors.
  • CONCLUSION: Cytologic or histologic confirmation of malignancy is imperative in patients with a pelvic mass, ascites, hydrothorax, and elevated CA 125 before initiating chemotherapy.
  • [MeSH-major] Brenner Tumor / complications. CA-125 Antigen / blood. Meigs Syndrome / etiology. Ovarian Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11704231.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


10. Zhang H, Kong B, Qu X, Jia L, Deng B, Yang Q: Biomarker discovery for ovarian cancer using SELDI-TOF-MS. Gynecol Oncol; 2006 Jul;102(1):61-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
  • OBJECTIVES: The purpose of this study is to discover potential biomarkers for the detection and monitoring of adjuvant chemotherapy for ovarian cancer.
  • METHODS: Serum samples from ovarian cancers and non-cancer controls were analyzed using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS).
  • To discover the possible diagnostic biomarker for ovarian cancer, a preliminary training set of spectra derived from 31 primary ovarian cancer patients, 16 patients with benign ovarian diseases, and 25 healthy women was used to develop a proteomic model that discriminated cancer from non-cancer effectively.
  • To explore treatment-induced serum protein change, the protein profiles generated from 16 postoperative patients before chemotherapy are compared with those obtained after chemotherapy.
  • One protein peak (mass/charge ratio [m/z], 4,475) was identified in 12 of 16 (75%) postoperative patients after chemotherapy, but was absent before chemotherapy.
  • CONCLUSION: The proteins represented by these peaks are candidate biomarkers for ovarian cancer diagnosis and/or monitoring treatment response.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood Proteins / analysis. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Proteomics / methods. Reproducibility of Results. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403569.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


11. Islam S, Yamout SZ, Gosche JR: Management and outcomes of ovarian masses in children and adolescents. Am Surg; 2008 Nov;74(11):1062-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management and outcomes of ovarian masses in children and adolescents.
  • Ovarian masses in the pediatric age group are rare, and malignancies are even less common.
  • We retrospectively reviewed the cases of ovarian masses in children in our institution over a 10-year period.
  • A total of 49 children and adolescents with ovarian masses were found.
  • These patients responded to chemotherapy, but there were three recurrences noted that responded to further therapy.
  • Seventy-four per cent of the benign tumors were teratomas.
  • The most common presentation was abdominal pain in 27 patients (55%) followed by an abdominal mass.
  • Ultrasound and CT scans were the most common imaging studies with a mean mass size of 14.7 cm.
  • A majority of the patients underwent a laparotomy with 12 per cent having a minimally invasive procedure.
  • Most ovarian masses in childhood are benign.
  • Malignant lesions have favorable outcomes with chemotherapy, even with recurrent disease.
  • Consideration for laparoscopic procedures should be given for the benign lesions.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Humans. Incidence. Laparoscopy. Laparotomy. Ovariectomy. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062661.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Milojkovic M, Hrgovic Z, Hrgovic I, Jonat W, Maass N, Buković D: Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis. Arch Gynecol Obstet; 2004 Mar;269(3):176-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of CA 125 serum level in discrimination between benign and malignant masses in the pelvis.
  • AIM: Our aim was to confirm that preoperative CA 125 serum level can be useful for discrimination between benign and malignant masses in the pelvis.
  • METHODS: Preoperative CA 125 serum level was analyzed retrospectively in 121 patients who had surgery because of a malignant ovarian tumor and in 91 patients with benign masses in the pelvis.
  • The cutoff serum level CA 125 between benign and malignant masses in the pelvis was 35 and 65 IU/ml.
  • RESULTS: Of those patients with a malignant ovarian tumor, 65.3% had menopause whereas only 31.5% of those with a benign tumor did so.
  • The average age of the patients with a malignant tumor was 54.2 years and of those with a benign tumor 46.8 years.
  • The preoperative CA 125 serum level was higher than 35 IU/ml in 80.2% and higher than 65 IU/ml in 72.7% of all analyzed patients with a malignant tumor, whereas it was 23.9% and 9.8% respectively in patients with a benign mass.
  • In early stage ovarian cancer disease (borderline stage, I/II) the preoperative CA 125 serum level was higher than 35 IU/ml in 67.8% and in 52.5% higher than 65 IU/ml.
  • After therapy the CA 125 serum level dropped below 35 IU/ml in 70.8% and after three chemotherapy courses in 78.1%.
  • A CA 125 level less than 35 IU/ml was achieved by therapy in 84.2% patients with an early stage disease (I/II) and in 62.1% in advanced stages (III/IV).
  • CONCLUSION: . Preoperative determination of CA 125 is a very useful method to discriminate between benign and malignant masses in the pelvis.
  • [MeSH-minor] Cystadenocarcinoma, Mucinous / blood. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / surgery. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Neoplasms / blood. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Predictive Value of Tests. Preoperative Care. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14557888.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


13. Kong F, Nicole White C, Xiao X, Feng Y, Xu C, He D, Zhang Z, Yu Y: Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol Oncol; 2006 Feb;100(2):247-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
  • OBJECTIVES: Early detection and monitoring the treatment remain the most important factors in improving long-term survival of ovarian cancer patients.
  • This study uses proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
  • METHODS: We analyzed protein profiles of three sets of sera using surface enhanced laser desorption and ionization time-of-light mass spectroscopy (SELDI-TOF-MS) on IMAC ProteinChip arrays and ProPeak software for bioinformatics data analysis.
  • The first set of patients included 21 ovarian cancers, 18 benign diseases, and 20 normal patients.
  • The second set included 32 ovarian cancers, 30 benign ovarian diseases, and 30 age-matched healthy controls.
  • The third set included samples collected before and after chemotherapy from 18 ovarian cancer patients.
  • RESULTS: Seven peaks were selected for their contribution to the separation of ovarian cancers from controls using the first and second set of samples.
  • CONCLUSIONS: Using SELDI-TOF analysis of 195 unique specimens, we discovered with preliminary validation six distinct peaks that may potentially be useful in the detection and monitoring of ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood Proteins / analysis. Neoplasm Proteins / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Computational Biology. Female. Humans. Middle Aged. Neoplasm Staging. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16229881.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


14. Chen CH, Huang CY, Chow SN: Early-stage ovarian carcinoma combined with pulmonary tuberculosis mimicking advanced ovarian cancer: a case report. Int J Gynecol Cancer; 2004 Sep-Oct;14(5):1007-11
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage ovarian carcinoma combined with pulmonary tuberculosis mimicking advanced ovarian cancer: a case report.
  • In patients of ovarian cancer combined with multiple pulmonary nodules, the diagnosis of metastatic ovarian cancer is always considered.
  • However, benign pulmonary conditions can be discovered instead.
  • An 80-year-old female presented with a rapidly growing ovarian mass, elevated serum CA-125, and multiple pulmonary varying-sized nodular lesions.
  • After surgery, her disease was allotted to 'stage IV' epithelial ovarian cancer and adjuvant cytotoxic chemotherapy was then used.
  • For fear of reactivation of pulmonary tuberculosis, the anticancer cytotoxic chemotherapy was postponed and the antituberculous treatment was given instead.
  • After 6-month course of antituberculous therapy, no active lung lesion was detectable.
  • We recommend that there must be positive cytologic or pathologic results of lung lesions to allot a case of ovarian cancer to stage IV.
  • Furthermore, whenever pulmonary lesions are seen on imaging, the possibility of diagnoses other than metastatic ovarian cancer should always be considered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / secondary. Neoplasm Staging. Ovarian Neoplasms / complications. Ovarian Neoplasms / pathology. Tuberculosis, Pulmonary / diagnosis. Tuberculosis, Pulmonary / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Radiography, Thoracic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361216.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Padungsutt P, Thirapagawong C, Senapad S, Suphanit I: Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy. Anticancer Res; 2000 Mar-Apr;20(2B):1291-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
  • This paper evaluates the usefulness of determining the level of serum Tissue Polypeptide Specific Antigen (TPS) by TPS ELISA in the diagnosis of ovarian malignancies and compares it with the results of histological examination of the ovaries.
  • The study covers 92 patients who had been clinically diagnosed with ovarian tumors by history, physical examination and pelvic examination with or without pelvic ultrasonography.
  • All of them underwent surgical treatment by exploratory laparotomy in Siriraj Hospital between May 1, 1996 and 31 March, 1997.
  • None of the patients had been treated with chemotherapy or hormonal therapy, and in no case were there any previously diagnosed malignancies.
  • TPS was measured in the serum of 92 patients who were preoperatively diagnosed with ovarian tumor: 52 patients had benign pelvic masses and 40 patients had malignant ovarian tumors.
  • Using the criterion for TPS positivity defined by the manufacturer (80 U/L), TPS levels were elevated in 28.8% of benign pelvic mass patients and in 90% of malignant ovarian tumor patients.
  • We conclude that determination of serum TPS level by TPS ELISA in the diagnosis of ovarian malignancy is good and clinically acceptable.
  • A TPS level greater than 80 U/L is a useful positivity criterion for screening for malignant ovarian tumors, while a TPS level greater than 180 U/L is a positivity criterion for differentiating malignant ovarian tumor from benign pelvic mass.
  • Because of its high false positive rate, any patient with TPS greater than 80 U/L should be further investigated for malignant ovarian tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / diagnosis. Pelvic Neoplasms / diagnosis. Peptides / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10810437.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] GREECE
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptides; 0 / tissue polypeptide specific antigen
  •  go-up   go-down


16. Tangjitgamol S, Hanprasertpong J, Manusirivithaya S, Wootipoom V, Thavaramara T, Buhachat R: Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes. Acta Obstet Gynecol Scand; 2010;89(2):182-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ovarian germ cell tumors: clinico-pathological presentation and survival outcomes.
  • OBJECTIVE: To evaluate clinico-pathological features, treatment, survival, and prognostic factors of patients with malignant ovarian germ cell tumors.
  • POPULATION: Malignant ovarian germ cell tumor patients treated between January 1996 and December 2007.
  • Patients with malignant tumors arising from benign cystic teratoma were excluded.
  • The most common complaint was pelvic or abdominal mass (63%).
  • Of 124 patients with available follow-up data, 22 did not receive adjuvant treatment; 1 had whole abdominal radiation; and 101 had chemotherapy.
  • CONCLUSIONS: Malignant ovarian germ cell tumors have a good prognosis with conservative surgical treatment.
  • Chemotherapy is important.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / mortality. Neoplasms, Germ Cell and Embryonal / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Child. Child, Preschool. Chorionic Gonadotropin, beta Subunit, Human / blood. Disease-Free Survival. Female. Humans. L-Lactate Dehydrogenase / blood. Neoplasm Recurrence, Local / pathology. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Young Adult. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961281.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


17. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD: Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol; 2005 Apr;192(4):1230-7; discussion 1237-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
  • OBJECTIVE: This study was undertaken to report on the benign gynecologic conditions occurring among women with an intact uterus at enrollment in the Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project.
  • STUDY DESIGN: The incidence rates of several benign gynecologic conditions were determined and risks were compared among women receiving tamoxifen and those receiving placebo, based on risk ratios (RRs) with 95% CIs.
  • Comparisons included stratification by menopausal status, body mass index, and history of estrogen use.
  • RESULTS: Compared with women taking placebo, premenopausal women taking tamoxifen had a greater incidence of endometrial polyps (RR = 1.9, 95% CI = 1.55-2.41), leiomyomas (RR = 1.3, 95% CI = 1.14-1.55), endometriosis (RR = 1.9, 95% CI = 1.35-2.70), ovarian cysts (RR = 1.5, 95% CI = 1.20-1.78), and gynecologic surgical procedures, including hysterectomy (RR = 1.6, 95% CI = 1.29-1.88).
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / therapy. Genital Diseases, Female / chemically induced. Genital Diseases, Female / pathology. Neoplasm Recurrence, Local / prevention & control. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Age Distribution. Aged. Chemotherapy, Adjuvant. Confidence Intervals. Dose-Response Relationship, Drug. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Probability. Reference Values. Risk Assessment

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2006 Apr;194(4):1204-5; author reply 1205 [16580343.001]
  • (PMID = 15846210.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


18. Atallah D, Checrallah A, Rouzier R, Ghossain MA, Chahine G: Retroperitoneal lymphangioleiomyoma mimicking ovarian tumor emerging after tamoxifen therapy. Obstet Gynecol; 2006 Sep;108(3 Pt 2):762-4
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymphangioleiomyoma mimicking ovarian tumor emerging after tamoxifen therapy.
  • A thoraco-abdominopelvic enhanced computed tomography scan showed a 22 x 21 x 12 cm well-encapsulated, complex pelvic mass.
  • An ovarian cystadenocarcinoma was suspected.
  • Surgery revealed a retroperitoneal mass that was removed with uterus and both adnexae.
  • We speculate that tamoxifen treatment may play a role in the development of this benign tumor.
  • [MeSH-major] Lymphangiomyoma / diagnosis. Ovarian Neoplasms. Retroperitoneal Neoplasms / diagnosis. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018494.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


19. Li M, Pan LY, Huang HF, Lang JH: [Epithelial ovarian tumors in adolescence: a study of clinical features and treatment]. Zhonghua Fu Chan Ke Za Zhi; 2004 Sep;39(9):598-601
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epithelial ovarian tumors in adolescence: a study of clinical features and treatment].
  • OBJECTIVE: To study the clinical feature, diagnosis and treatment of epithelial ovarian tumors in adolescent patients.
  • METHODS: A retrospective analysis was performed on 29 patients of epithelial ovarian tumors between the age of 13 and 19 during the period of 1983 - 2002 in Peking Union Medical College Hospital.
  • Twenty of the cases were with benign tumors, four with borderline, and five with malignant tumors.
  • The majority of patients presented with abdominal pain, abdominal distention and a large pelvic mass.
  • The histological types included mucinous tumor in twenty-two cases, serous tumor in six, and endometroid tumor in one case.
  • Of benign tumor group, an abdominal unilateral salpingo-oophorectomy was performed on nine cases.
  • A cisplatin combined chemotherapy was given to four patients with malignant tumors.
  • CONCLUSIONS: The incidence of epithelial ovarian tumors during adolescence increases with age.
  • Mucinous tumor is the most common histological type in adolescent patients.
  • A laparoscopic cystectomy could be considered for most benign patients.
  • The therapeutic strategy should be individualized, and surgical approach should consider both cure and preservation of fertility in malignant cases.
  • [MeSH-major] Carcinoma / therapy. Ovarian Neoplasms / therapy. Puberty
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Female. Humans. Laparoscopy. Neoplasm Staging. Ovary / surgery. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15498186.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Loeffen JL, Wijnen M, Schijf CP, van Wieringen P: [Ovarian tumour in a girl with chronic abdominal pain and distension]. Ned Tijdschr Geneeskd; 2006 Mar 25;150(12):677-80
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian tumour in a girl with chronic abdominal pain and distension].
  • Ovarian tumours are rarely seen in children.
  • Even though these tumours may contain histologically malignant characteristics, their behaviour is usually benign.
  • In addition, pressure from the tumour mass may result in symptoms in adjacent organ systems.
  • Patients with advanced disease may benefit from adjuvant chemotherapy.
  • Chronic abdominal pain is frequently observed in children and, in some rare cases, may be caused by ovarian tumours.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Sertoli Cell Tumor / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613252.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


21. De Backer A, Madern GC, Oosterhuis JW, Hakvoort-Cammel FG, Hazebroek FW: Ovarian germ cell tumors in children: a clinical study of 66 patients. Pediatr Blood Cancer; 2006 Apr;46(4):459-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian germ cell tumors in children: a clinical study of 66 patients.
  • BACKGROUND: Ovarian germ cell tumors are rare in childhood.
  • The aim of this study is to review clinical presentation, management, and outcome in a two-center series of girls with ovarian germ cell tumor.
  • PROCEDURE: The records of 66 patients (median age 9 years) with histologically proven ovarian germ cell tumor (either benign or malignant), treated over a 44-year-span, were reviewed.
  • RESULTS: Pain and an abdominal mass were the most frequent symptoms.
  • Unilateral salpingo-oophorectomy was the most frequently performed procedure (n = 46), and ovarian-sparing tumorectomy was performed in 9 patients (one bilaterally).
  • Surgical removal of the tumor with or without the ovary and/or adnex was the sole treatment in 55 patients, chemotherapy was administered in 10 and radiotherapy + chemotherapy in one.
  • The 64 survivors are now between 8 months and 44 years after treatment.
  • CONCLUSIONS: With a recurrence rate of 4.5% and a mortality rate of 3%, this series confirms the excellent prognosis for girls with ovarian germ cell tumor (GCT).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206211.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


22. Ngom G, Cisse M, Fall I, Sankale AA, Konate I, Ndoye M: [The ovarian tumors in children. A report of 12 cases]. Dakar Med; 2004;49(1):57-60
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The ovarian tumors in children. A report of 12 cases].
  • We collected in a retrospective study 12 cases of ovarian tumors during 30 years.
  • The medical imagery (echography, intravenous urography, Chest X-ray) permitted to evoke in the majority of the cases the ovarian origin of the mass.
  • The surgical treatment consisted in an ovariectomy (5 times), an salpingo - ovariectomy (6 times) and a surgery of partial exeresis associated to a chemotherapy.
  • The histological exam of the operative piece showed that it was about benign tumors.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Ovariectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15782479.001).
  • [ISSN] 0049-1101
  • [Journal-full-title] Dakar médical
  • [ISO-abbreviation] Dakar Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Senegal
  •  go-up   go-down


23. Gungor T, Altinkaya SO, Akbay S, Bilge U, Mollamahmutoglu L: Malign mural nodules associated with serous ovarian tumor of borderline malignancy: a case report and literature review. Arch Gynecol Obstet; 2010 Mar;281(3):485-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malign mural nodules associated with serous ovarian tumor of borderline malignancy: a case report and literature review.
  • BACKGROUND: Cystic tumors of ovary, whether benign, borderline, or malignant may be associated with mural nodule of various types, including sarcomas, sarcoma-like mural nodules (SLMN), and foci of anaplastic carcinoma.
  • Cases of serous borderline ovarian tumor with mural nodules of mixed type are very rare.
  • Imaging studies revealed a huge mass localized in pelvis and lower abdomen and grade 1-2 left renal hydronephrosis.
  • In exploratory laparotomy there was a 16 cm mass adherent to lateral abdominal wall and intestines.
  • Left ureter was found to be dilated because of the infiltration of distal part by the tumor, so distal ureteral resection and neoureterocystostomy were performed.
  • Final pathology revealed borderline serous ovarian tumor with mural nodules which were consisted of SLMNs, multiple and sharply demarcated from the adjacent tumor, and sarcomatous nodules showing infiltrative appearance in metastatic regions.
  • She had postoperative chemotherapy and follow-up is going on without metastases in her first year.
  • CONCLUSION: The existence of sarcomatous nodules combined with the SLMN necessitates a careful histologic analysis for treatment and the determination of prognosis.
  • However, too few cases of mixed type mural nodules have been published to warrant a conclusion regarding their prognosis.
  • [MeSH-major] Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597831.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


24. Allen GW, Forouzannia A, Bailey HH, Howard SP: Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125. Gynecol Oncol; 2004 Sep;94(3):811-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125.
  • BACKGROUND: We report a case of pelvic lymphoma with an elevated serum CA-125 level, initially misdiagnosed as ovarian carcinoma.
  • A review of the literature is presented and a possible mechanism for CA-125 elevation in diseases other than ovarian cancer is discussed.
  • Workup revealed a pelvic mass and an elevated CA-125 level.
  • Paclitaxel and carboplatin were administered to facilitate therapy and provide symptomatic relief for a presumed bulky ovarian carcinoma.
  • A biopsy was obtained after the initiation of chemotherapy, yielding the diagnosis of diffuse large B cell non-Hodgkin's lymphoma, stage II-B.
  • A search of the literature revealed several clinical series describing the elevation of CA-125 in a variety of diseases, both benign and malignant.
  • CONCLUSIONS: In the setting of a newly diagnosed pelvic mass, care should be taken when interpreting an elevated CA-125 level.
  • While ovarian cancer is high on the list of differential diagnoses, lymphoma cannot be excluded until a tissue diagnosis is obtained.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15350377.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


25. Veras E, Deavers MT, Silva EG, Malpica A: Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol; 2007 May;31(5):774-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
  • The most common presentation was abdominal/pelvic pain (6 cases), followed by ascites (2 cases), pelvic mass, vaginal bleeding, and abdominal bloating (1 case each).
  • A single case was associated with a benign ovarian cyst.
  • NSCNEC represented anywhere from 10% to 90% of the ovarian tumor.
  • Seven patients were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by chemotherapy.
  • One patient had a bilateral salpingo-oophorectomy with omentectomy and appendectomy followed by chemotherapy; 1 patient had a total abdominal hysterectomy with right salpingo-oophorectomy followed by chemotherapy; one had a bilateral salpingo-oophorectomy followed by chemotherapy, and one had a right salpingo-oophorectomy with appendectomy followed by chemotherapy.
  • In summary, ovarian NSCNEC is an aggressive tumor with a tendency to present at advanced stage and cause death within a mean of 17 months after diagnosis; however, some patients, particularly those with stage I disease and/or those who have received platinum-based therapy, may have a more favorable prognosis.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Neuroendocrine / pathology. Immunoenzyme Techniques. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Staging. Neoplasms, Multiple Primary. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460463.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


26. Cass DL, Hawkins E, Brandt ML, Chintagumpala M, Bloss RS, Milewicz AL, Minifee PK, Wesson DE, Nuchtern JG: Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period. J Pediatr Surg; 2001 May;36(5):693-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery for ovarian masses in infants, children, and adolescents: 102 consecutive patients treated in a 15-year period.
  • BACKGROUND/PURPOSE: Ovarian pathology, although rare in children, must be included in the differential diagnosis of all girls who present with abdominal pain, an abdominal mass, or precocious puberty.
  • METHODS: To improve clinical appreciation of these lesions, the authors reviewed the presentation, evaluation, and outcome of all patients with ovarian pathology surgically treated at their institution since 1985.
  • RESULTS: One hundred two girls (aged 9.8 +/- 5.5 years; range, 2 days to 20 years) underwent 106 separate ovarian operations (43 salpingo-oophorectomies, 21 oophorectomies, 33 ovarian cystectomies, and 9 ovarian biopsies).
  • Of those presenting with acute abdominal pain (n = 59), 25 (42%) had ovarian torsion (14 associated with a mature teratoma), and only 1 (2%) had a malignant tumor.
  • In contrast, of those presenting with an abdominal mass (n = 23), 6 (26%) had malignancies.
  • There was no age difference between those with benign disease (9.9 +/- 5.6 years; n = 96) and those with malignant tumors (8.6 +/- 3.9 years, n = 10).
  • These patients all had unilateral salpingo-oophorectomy, 4 had chemotherapy, and all are now disease free at 8.4 +/- 4.1 years follow-up.
  • CONCLUSION: Ovarian pathology remains a rare indication for surgery in girls less than 20 years of age.
  • Because most of these lesions are benign, ovarian-preserving operations should be performed whenever feasible.
  • [MeSH-major] Ovarian Neoplasms / surgery. Ovariectomy / methods. Ovariectomy / statistics & numerical data
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Adult. Age Distribution. Age Factors. Age of Onset. Biopsy. Child. Child, Preschool. Diagnosis, Differential. Disease-Free Survival. Fallopian Tubes / surgery. Female. Follow-Up Studies. Hospitals, Pediatric. Humans. Infant. Infant, Newborn. Omentum / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11329568.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Naik R, Cross P, Lopes A, Godfrey K, Hatem MH: "True" versus "apparent" stage I epithelial ovarian cancer: value of frozen section analysis. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:41-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "True" versus "apparent" stage I epithelial ovarian cancer: value of frozen section analysis.
  • The aim of this prospective study was to determine the clinical benefits of introducing peroperative frozen section analysis into the surgical management policy of women referred with an adnexal mass suspicious of ovarian cancer.
  • Paraffin section diagnoses included 74 benign tumors, 11 borderline tumors, 34 primary epithelial cancers, 5 nonepithelial cancers, and 6 metastatic tumors.
  • All primary epithelial ovarian cancers were correctly identified as requiring a staging procedure based on the frozen section result.
  • Four of seventy-four cases reported as benign on frozen section analysis were underdiagnosed; two were later diagnosed on paraffin section as borderline tumors and a further two as malignant (one low-grade adenosarcoma and one primary peritoneal cancer).
  • Of the 130 cases, 55 (42.3%) underwent a staging procedure based on the frozen section result.
  • The value of frozen section analysis in determining the need for the performance of a staging procedure had the following statistical test results: sensitivity = 92%, specificity = 88%, positive predictive value = 82%, and negative predictive value = 95%.
  • Excluding the borderline tumors, metastatic tumors, and primary peritoneal tumor where staging did not impact subsequent clinical management, the statistical test results for frozen section analysis in determining the need for a staging procedure were sensitivity = 97%, specificity = 95%, positive predictive value = 90%, and negative predictive value = 99%.
  • The clinical benefits of introducing frozen section analysis in the surgical staging policy of women with an adnexal mass suspicious of ovarian malignancy included avoidance of a surgical staging procedure in 95% of cases identified on paraffin section analysis to be benign.
  • This benefit was without compromising the avoidance of chemotherapy in true stage I epithelial ovarian cancer cases.
  • [MeSH-major] Frozen Sections. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515566.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Amsalem H, Nadjari M, Prus D, Hiller N, Benshushan A: Growing teratoma syndrome vs chemotherapeutic retroconversion: case report and review of the literature. Gynecol Oncol; 2004 Jan;92(1):357-60
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Immature ovarian teratoma is the third most common germ cell tumor (GCT) following dysgerminoma and endodermal sinus tumor.
  • The treatment of choice during childbearing age for immature teratoma composes of unilateral oophorectomy and in case of metastatic disease postoperative chemotherapy (BEP).
  • Finding a solid mass in the peritoneal or chest cavity during routine follow up raises the suspicion of distance recurrence.
  • DiSaia was the first to describe the appearance of benign distant metastasis during routine follow up.
  • CASE: We present a case of a 12-year-old girl treated for growing teratoma syndrome after primary ovarian GCT.
  • [MeSH-major] Abdominal Neoplasms / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Pelvic Neoplasms / secondary. Teratoma / drug therapy. Teratoma / secondary

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14751185.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 14
  •  go-up   go-down


29. Guo H, Keefe KA, Kohler MF, Chan JK: Juvenile granulosa cell tumor of the ovary associated with tuberous sclerosis. Gynecol Oncol; 2006 Jul;102(1):118-20
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Tuberous sclerosis is a neurocutaneous syndrome characterized by benign tumors that can affect many organs.
  • She presented with a 20 x 22 cm pelvic mass and received a right salpingo-oophorectomy.
  • Three months later, she recurred and underwent a left salpingo-oophorectomy, lymphadenectomy, and omentectomy followed by four cycles of Bleomycin, Etoposide, and Cisplatin chemotherapy.
  • CONCLUSION: Treatment options and a review of the literature pertaining to juvenile ovarian granulosa cell tumors and tuberous sclerosis are discussed.
  • [MeSH-major] Granulosa Cell Tumor / complications. Ovarian Neoplasms / complications. Tuberous Sclerosis / complications

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516278.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K: New tumor markers: CA125 and beyond. Int J Gynecol Cancer; 2005 Nov-Dec;15 Suppl 3:274-81
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A variety of biomarkers have been developed to monitor growth of ovarian cancer and to detect disease at an early interval.
  • CA125 (MUC16) has provided a useful serum tumor marker for monitoring response to chemotherapy, detecting disease recurrence, distinguishing malignant from benign pelvic masses, and potentially improving clinical trial design.
  • A rapid fall in CA125 during chemotherapy predicts a favorable prognosis and could be used to redistribute patients on multiarmed randomized clinical trials.
  • Serial measurement of CA125 might also provide a useful marker for monitoring stabilization of disease with cytostatic targeted therapeutic agents.
  • The greatest potential for serum markers may be in detecting ovarian cancer at an early stage.
  • An algorithm has been developed that calculates risk of ovarian cancer based on serial CA125 values and refers patients at highest risk for Tvs. Use of the algorithm is currently being evaluated in a trial with 200,000 women in the UK that will test critically the ability of a two-stage screening strategy to improve survival in ovarian cancer.
  • Whatever the outcome, as 20% of ovarian cancers have little or no expression of CA125, additional serum markers will be required to detect all patients in an initial phase of screening.
  • Two proteomic approaches have been used: one examines the pattern of peaks on mass spectroscopy and the other uses proteomic analysis to identify a limited number of critical markers that can be assayed by more conventional methods.
  • Mathematical techniques are being developed to analyze combinations of marker levels to improve sensitivity and specificity.
  • In the future, serum markers should improve the sensitivity of detecting recurrent disease as well as facilitate earlier detection of ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Neoplasms, Glandular and Epithelial / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343244.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA83639
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  • [Number-of-references] 50
  •  go-up   go-down


31. Lo Curto M, D'Angelo P, Cecchetto G, Klersy C, Dall'Igna P, Federico A, Siracusa F, Alaggio R, Bernini G, Conte M, De Laurentis T, Di Cataldo A, Inserra A, Santoro N, Tamaro P, Indolfi P: Mature and immature teratomas: results of the first paediatric Italian study. Pediatr Surg Int; 2007 Apr;23(4):315-22
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Teratoma is the most common germ cell tumour in childhood; mature (MT) and immature teratomas (IT) are benign tumours, but if they recur, they can be in some cases malignant.
  • Clinical data, treatment and results were all analysed.
  • Chemotherapy (CT) with Vinblastine, D: -actinomycin and cyclophosphamide was indicated for extra-testicular IT grade 2 or 3.
  • A malignant recurrence occurred in two patients with sc tumours (after partial resection in one and after biopsy + CT in one) and in one patient with ovarian IT after a partial resection.
  • All the patients underwent surgical excision of the recurred mass; CT according to Protocol for Malignant GCT was administered to those who had malignant recurrence; 122/126 patients with MT and 53/56 with IT are alive without disease with a follow up of 8-144 months (median 56).
  • [MeSH-major] Ovarian Neoplasms / epidemiology. Teratoma / epidemiology. Testicular Neoplasms / epidemiology
  • [MeSH-minor] Age Distribution. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Incidence. Infant. Infant, Newborn. Italy / epidemiology. Male. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):228-34 [9293455.001]
  • [Cites] J Pediatr Surg. 2001 Jan;36(1):12-7 [11150431.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2137-43 [10561269.001]
  • [Cites] Med Pediatr Oncol. 2003 Nov;41(5):417-25 [14515380.001]
  • [Cites] J Pediatr Surg. 1992 Aug;27(8):1075-8; discussion 1078-9 [1403540.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):620-4 [9053485.001]
  • [Cites] J Pediatr Surg. 1987 Mar;22(3):274-7 [3559872.001]
  • [Cites] Med Pediatr Oncol. 1998 Jul;31(1):8-15 [9607423.001]
  • [Cites] Ann Surg. 1965 Dec;162(6):1091-5, 1100 [5845591.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(2):99-110 [2163259.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):171-6 [9498381.001]
  • [Cites] Cancer. 1989 May 1;63(9):1657-67 [2467734.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):169-75 [14752882.001]
  • [Cites] Crit Rev Oncol Hematol. 1990;10(2):89-98 [1694438.001]
  • [Cites] Med Pediatr Oncol. 1993;21(6):395-401 [8390599.001]
  • [Cites] Am J Obstet Gynecol. 1999 Aug;181(2):353-8 [10454682.001]
  • [Cites] J Pediatr Surg. 1974 Jun;9(3):389-98 [4843993.001]
  • [Cites] Cancer. 1976 May;37(5):2359-72 [1260722.001]
  • [Cites] AJR Am J Roentgenol. 1981 Aug;137(2):395-8 [6789651.001]
  • (PMID = 17333214.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


32. Leonard GD, Low JA, Berman AW, Swain SM: CA 125 elevation in breast cancer: a case report and review of the literature. Breast J; 2004 Mar-Apr;10(2):146-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 69-year-old postmenopausal woman with newly diagnosed inflammatory breast cancer was evaluated for a pelvic mass found incidentally during staging computed tomography (CT) scans.
  • She was begun on primary chemotherapy and her CA 125 normalized.
  • CA 125 is a tumor-associated antigen that is most commonly seen in advanced ovarian cancer.
  • It is predominantly derived from coelomic epithelium, which explains elevations in benign conditions or other malignancies.
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Diagnosis, Differential. Doxorubicin / administration & dosage. Edema / etiology. Female. Humans. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15009043.001).
  • [ISSN] 1075-122X
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Taxoids; 15H5577CQD / docetaxel; 2S9ZZM9Q9V / Bevacizumab; 80168379AG / Doxorubicin
  • [Number-of-references] 22
  •  go-up   go-down


33. Demirci H, Erdamar H, Karakoc A, Akturk M, Yilmaz M, Arslan M: CA 72-4 levels in patients with type 2 diabetes mellitus. Int J Clin Pract; 2010 Jan;64(1):34-8
MedlinePlus Health Information. consumer health - Diabetes Type 2.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CA 72-4 levels in patients with type 2 diabetes mellitus.
  • OBJECTIVE: CA 72-4 is one of the blood group carbohydrate antigens which can be used as a tumour marker in ovarian, pancreatic and gastrointestinal carcinomas.
  • It can also be elevated in various benign conditions including pancreatitis.
  • In this study, we investigated CA 72-4 levels in patients with type 2 diabetes and its relation to the metabolic status.
  • METHODS: Sixty-nine patients with type 2 diabetes mellitus (female/male = 40/29) and 60 healthy subjects (female/male = 35/25) participated in this study.
  • Patients had a pathological finding for any of these two parameters were further investigated with upper gastrointestinal endoscopy, colonoscopy and computerised tomography.
  • There was no association between CA 72-4 levels and age and sex of the patients, duration of diabetes, body mass index, biochemical indicators of metabolic control (the levels of HbA(1c), fasting and postprandial glucose, serum lipids), the presence of microvascular complications (retinopathy, nephropathy, neuropathy) or treatment modalities.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / metabolism. Diabetes Mellitus, Type 2 / immunology. Diabetic Angiopathies / immunology
  • [MeSH-minor] Blood Glucose / metabolism. Drug Therapy, Combination. Female. Hemoglobin A, Glycosylated / metabolism. Humans. Hypoglycemic Agents / therapeutic use. Insulin / therapeutic use. Lipids / blood. Male. Microcirculation. Middle Aged. Occult Blood

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes, Type 2.
  • Genetic Alliance. consumer health - Diabetes mellitus type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18205795.001).
  • [ISSN] 1742-1241
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Blood Glucose; 0 / CA-72-4 antigen; 0 / Hemoglobin A, Glycosylated; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Lipids
  •  go-up   go-down






Advertisement